EGFR is tagged by c-Cbl/Grb2 for breakdown inside lysosomes. In hypoxia (right), the RNA molecule EUDAL prevents this process, keeping EGFR permanently active. This activates the STAT3/BNIP3 pathway, ...
The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become ...
New insights to gene expression signatures from primary FFPE tumors for the prediction of response to cetuximab in KRAS and BRAF wild-type colorectal cancer (CRC). Background: KRAS mutated CRC ...
Two microscopy images of human colon organoids. The left image shows an organoid with the FBXW7 mutation (colorectal cancer) and the right image shows an organoid without the mutation (wild type). The ...
An expert discusses the MARIPOSA study’s impact on managing central nervous system (CNS) involvement in EGFR-mutated non–small cell lung cancer, emphasizing improved brain progression-free survival, ...
Treating constipation with lubiprostone may confer renal benefits in chronic kidney disease by modulating microbiome-driven ...
Conclusions: Lack of phosphorylation of AKT and lack of PTEN expression in the AKT pathway downstream of EGFR may be a mechanism of MPM's clinical resistance to OSI-774. ERK is variably activated ...
Edward Arrowsmith, MD, MPH, medical director for clinical pathways for OneOncology, discussed treatment challenges in EGFR Exon 20 insertion+ non-small cell lung cancer (NSCLC) and best practices in ...
Please provide your email address to receive an email when new articles are posted on . A number of epidermal growth factor receptor inhibitors used in the oncology setting continue to demonstrate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback